In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
about
Current and emerging azole antifungal agentsIn vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogensIn vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and CandidaAntifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemiaIn vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformansInteractions of posaconazole and flucytosine against Cryptococcus neoformansComparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeastsIn vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformansIn vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida sppActivity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiaeAntiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hostsIn vitro and in vivo activities of posaconazole against Coccidioides immitis.In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis.Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsPharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatusIn vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.Posaconazole: An Update of Its Clinical Use.Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.
P2860
Q24550733-A35847F2-A29F-46D2-975F-15A7C25CBC13Q28343832-39998D14-62F0-41B8-8245-27012BFB54C1Q28344464-6875B54D-3B94-4D96-882B-414CE7DC59F3Q28349552-8591EE90-13F1-4BDD-926A-54C870D5A118Q28353303-0F681A52-FE3A-44C2-9C73-834F32A1E2DDQ28362562-26B97C80-FFEC-4221-A5EF-9D687BB6AE85Q28368930-8D8EB47C-C35E-423C-8841-1D58A487D155Q28369024-A6BA720B-D673-4C2C-8740-29B18A0C7A83Q28369323-89250B0C-0A53-455C-B00F-B5D888642B48Q28379177-C1CA0664-F39F-47D4-8071-18A9A88EFB1DQ28379453-3204DBA8-4693-4C0E-A87B-C2C45BA81CA3Q33694317-691A30C2-2E5E-4817-B111-1B645342B00BQ33976048-232B22CD-4158-476A-8CCF-CC02970CF7BDQ33978515-75D85317-29D9-47CC-909A-2F32DD71F471Q34107135-25E8B7EB-B280-4275-B21F-92E5AC224E1CQ34680661-1E20281A-B76A-45B4-989E-D3761808F496Q34882440-C8E14069-F324-4323-9556-655F42DAFD76Q35077994-911201AF-B8F3-4656-81AE-9B30643BBCEDQ35685548-EC27C726-B57F-41CB-9719-0D41E3C2BEF5Q39473214-F57A81FF-AF3D-4610-B315-86CF999D0C01Q39784524-82D2C937-8993-40F7-BB4A-CDB16CC61B49Q40469499-77BCDE0C-3B47-40E3-AA7B-231B4AD02436Q41848545-F3398C23-1F93-4DE4-BEF8-D15340A3F15EQ42144246-7D00B315-BCC6-4AAB-A225-149AA636C3B0Q42154719-183AFB3E-D7A5-4009-8339-BAADAF520D25
P2860
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@ast
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@en
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@nl
type
label
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@ast
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@en
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@nl
prefLabel
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@ast
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@en
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@nl
P2093
P2860
P356
P1476
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
@en
P2093
P2860
P304
P356
10.1128/AAC.40.8.1910
P407
P577
1996-08-01T00:00:00Z